ReviewFrontiers in psychiatry2022
The economics of psychedelic-assisted therapies: A research agenda.
Review in Frontiers in psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 41 citations in OpenAlex.
- Novel approaches in depression treatment: from rapid-acting antidepressants to personalized interventions.Molecular psychiatry · 2026Review
- Characterizing non-hallucinogenic psychedelics beyond the head twitch response: phenotypic fingerprinting of lisuride and LSD.Translational psychiatry · 2026Article
- Bringing Psilocybin-Assisted Therapy to Palliative Oncology: Early Lessons from Real-World Implementation.Healthcare (Basel, Switzerland) · 2026Article
- Trials, trips, and tribulations: pathways for implementing psychedelic therapy in Ireland.The international journal of neuropsychopharmacology · 2026Review
- Not a Standalone Treatment: Considerations for Psychedelic-Assisted Therapy.Brain and behavior · 2026Review
- On the meaning of "plasticity" in neuroscience and mental health research and its relation to the action of psychedelic therapy.Frontiers in neuroscience · 2026Article
- A phase 1 study of a second experience with Group Retreat Psilocybin Therapy for partial responders after a first experience.Frontiers in public health · 2026Article
- Review
- Simple Analogs of the LSD D-Ring: A Consideration of Structure-Activity Relationships and Their Potential as Therapeutics.ACS chemical neuroscience · 2025Review
- Prevalence and Health Care Utilization of Posttraumatic Stress Disorder and Other Trauma-Related Mental Health Diagnoses in a Large, Integrated Health Care System.The Permanente journal · 2025Article
- Psilocybin-assisted therapy for treatment-resistant depression in the US: a model-based cost-effectiveness analysis.Translational psychiatry · 2025Article
- The Relationships Between Healthcare Access, Gender, and Psychedelics and Their Effects on Distress.Healthcare (Basel, Switzerland) · 2025Article
- A systematic review of income and education reporting in psychedelic clinical trials.Nature. Mental health · 2025Article
- Psychedelic Drugs in Mental Disorders: Current Clinical Scope and Deep Learning-Based Advanced Perspectives.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Protocol of an open-label safety and feasibility pilot study of ketamine-assisted psychotheraBMJ open · 2025Article
- Use of psychedelic treatments in psychiatric clinical practice: an EPA policy paper.European psychiatry : the journal of the Association of European Psychiatrists · 2025Article
- Article
- The influence of stakeholder interests on safety outcome reporting in psychedelic research and implications for science communication.Trends in psychiatry and psychotherapy · 2025Article
- Psychedelic training program development: lessons from the evolution of the EMBARK program.Frontiers in psychology · 2025Article
- Psychedelics assisting therapy, or therapy assisting psychedelics? The importance of psychotherapy in psychedelic-assisted therapy.Frontiers in psychology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
After a long hiatus, psychiatry is undergoing a resurgence of interest in psychedelic drugs as therapy for a wide range of mental health disorders Accumulating clinical evidence suggests substantial potential for psychedelics used in a therapeutic context, as treatment for, among other disorders, depression, post-traumatic stress disorder (PTSD), and addictions to tobacco, opioids and alcohol. As soon as 2024, powerful new therapeutic modalities could become available for individuals with mental health problems refractory to traditional therapies. Yet research has lagged on economic considerations, such as costs and cost-effectiveness, the economic effects of widespread implementation, pricing, and economic appraisal's methodological considerations relevant to psychedelic therapies. These issues are critical if psychedelic therapies are to become widely accessible. We describe six types of economic analyses and their rationale for decisions and planning including the needs of health care payers. We also outline desirable features of this research, including scientific rigor, long horizons, equity, and a global view.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.